129 related articles for article (PubMed ID: 38709961)
1. Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent Reforms.
Bertuzzi L; Maini L
Health Aff (Millwood); 2024 May; 43(5):717-724. PubMed ID: 38709961
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Socal MP; Ezebilo I; Bai G; Anderson GF
Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
[TBL] [Abstract][Full Text] [Related]
3. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
4. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
5. Coverage of New Drugs in Medicare Part D.
Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
[TBL] [Abstract][Full Text] [Related]
6. Implications of health reform for retiree health benefits.
Fronstin P
EBRI Issue Brief; 2010 Jan; (338):1-17. PubMed ID: 20104796
[TBL] [Abstract][Full Text] [Related]
7. ERISA Reform as Health Reform: The Case for an ERISA Preemption Waiver.
McCuskey EY
J Law Med Ethics; 2020 Sep; 48(3):450-461. PubMed ID: 33021183
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy benefit caps and the chronically ill.
Joyce GF; Goldman DP; Karaca-Mandic P; Zheng Y
Health Aff (Millwood); 2007; 26(5):1333-44. PubMed ID: 17848444
[TBL] [Abstract][Full Text] [Related]
9. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
10. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
11. Socioeconomic differences in Medicare supplemental coverage.
Pourat N; Rice T; Kominski G; Snyder RE
Health Aff (Millwood); 2000; 19(5):186-96. PubMed ID: 10992668
[TBL] [Abstract][Full Text] [Related]
12. Retiree health benefits.
Morrisey MA
Annu Rev Public Health; 1993; 14():271-92. PubMed ID: 8323590
[TBL] [Abstract][Full Text] [Related]
13. Massachusetts health reform: high costs and expanding expectations may weaken employer support.
Draper DA; Felland LE; Liebhaber A; Lauer JR
Issue Brief Cent Stud Health Syst Change; 2008 Oct; (124):1-6. PubMed ID: 19024889
[TBL] [Abstract][Full Text] [Related]
14. Health benefits in 2013: moderate premium increases in employer-sponsored plans.
Claxton G; Rae M; Panchal N; Damico A; Whitmore H; Bostick N; Kenward K
Health Aff (Millwood); 2013 Sep; 32(9):1667-76. PubMed ID: 23962411
[TBL] [Abstract][Full Text] [Related]
15. Patients' access to 2018 FDA-approved drugs 1 year post approval.
Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
[TBL] [Abstract][Full Text] [Related]
16. Why Did Employer Coverage Fall In Massachusetts After The ACA? Potential Consequences Of A Changing Employer Mandate.
Sommers BD; Shepard M; Hempstead K
Health Aff (Millwood); 2018 Jul; 37(7):1144-1152. PubMed ID: 29985692
[TBL] [Abstract][Full Text] [Related]
17. Medicare and employer-sponsored health insurance.
Gottlich V
Issue Brief Cent Medicare Educ; 2000; 1(9):1-8. PubMed ID: 11817419
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Coverage Restrictions on Antipsychotic Utilization Among Low-Income Medicare Part D Enrollees.
Roberto PN; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
Adm Policy Ment Health; 2017 Nov; 44(6):943-954. PubMed ID: 28660370
[TBL] [Abstract][Full Text] [Related]
19. Approval of information collection requirements for the joint interim rules for health insurance portability for group health plans, and the individual market health insurance reform: portability from group to individual coverage; federal rules for access in the individual market; state alternative mechanisms to federal rules--IRS, DOL, HCFA. Interim rules with request for comments; approval of information collection requirements.
Fed Regist; 1997 Jul; 62(127):35904-6. PubMed ID: 10169019
[TBL] [Abstract][Full Text] [Related]
20. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
